临床无肌病性皮肌炎生物学标记物研究进展  

Research progress on biomarkers in clinically amyopathic dermatomyositis

作　　者：左瑜[1] 安媛[1] 栗占国[1] 

机构地区：[1]北京大学人民医院风湿免疫科,北京100044

出　　处：《实用医院临床杂志》2015年第5期1-4,共4页Practical Journal of Clinical Medicine

摘　　要：临床无肌病性皮肌炎(clinically amyopathic dermatomyositis,CADM)作为炎性肌病中亚型之一,临床上较难识别,并可合并肺间质病变及恶性肿瘤,部分患者病情进展迅速,预后较差。因此,通过测定生物标记物及病情活动监测指标对CADM患者早期诊断及治疗具有重要意义。本文对CADM的流行病学情况、相关生物学标记物及其临床意义进行讨论。Clinically amyopathic dermatomyositis （CADM） is a unique subset of idiopathic inflammatory myositis. Atypical clinical manifestations and associated ILD/malignancy often result in rapid progress and poor prognosis in some patients with CADM. Thus, the detection of biomarkers and treatment monitor indexes is very important for early diagnosis and treatment of the disease. This review will discuss the epidemiologic status, and relative biomarkers and their clinical significance in the disease.

关 键 词：临床无肌病性皮肌炎 生物学标记物 自身抗体 

分 类 号：R593.2[医药卫生—内科学]